Format

Send to

Choose Destination
See comment in PubMed Commons below
Metabolism. 2006 May;55(5 Suppl 1):S2-5.

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

Author information

1
Diabetes Trials Unit, OCDEM, University of Oxford, Oxford OX3 7LJ, UK.

Abstract

The United Kingdom Prospective Diabetes Study shows sulfonylureas to be an effective first-line therapy for people with type 2 diabetes mellitus. The durability of the glycemic control obtained is dependent on the degree to which beta-cell function can be maintained, but sulfonylureas appear neither to increase nor to decrease the underlying rate of loss of beta-cell function. As sulfonylureas act by enhancing insulin secretion, they are probably best used close to the time when diabetes is diagnosed when beta-cell function is at its greatest and their utility can be extended by judicious use in combination with agents that improve glycemia by different modes of action, including insulin.

PMID:
16631806
DOI:
10.1016/j.metabol.2006.02.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center